Back to
BALYASNY ASSET MANAGEMENT L.P.
CHRS
Showing 0 of 13 quarters
Position history for
BALYASNY ASSET MANAGEMENT L.P.'s holdings in COHERUS ONCOLOGY INC
No. Balyasny Asset Management exited its CHRS (Coherus Oncology) position in Q1 2024. Its Q4 2023 13F listed 62,451 shares worth $207,962. Balyasny Asset Management already held CHRS in its Q4 2018 13F, the earliest on record, and held it in 10 quarterly 13F filings.
Current Value
—
Current Shares
—
Total Value Change
$0
Total Shares Change
0
No position history available for this security.